Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Novo obesity drug seen with 43 percent chance of approval
2 views
Skip to first unread message
Sweet Zombie Jesus
May 25, 2012, 12:52:05 PM5/25/12
to
Novo obesity drug seen with 43 percent chance of approval
10:17 a.m. CDT, May 24, 2012
COPENHAGEN (Reuters) - Danish group Novo Nordisk's diabetes drug
Victoza has a 43 percent chance of being approved as an obesity
treatment in the United States, according to a Reuters poll which
found Danish bank analysts had the highest expectations.
Novo Nordisk, the world's biggest insulin producer, is in phase three
of studies to use Victoza to treat obesity and expects the treatment
to be launched in the United States late in of 2014 or early 2015.
Liraglutide, an active ingredient in Victoza, has shown it can be
effective in helping obese people losing weight.
A survey of 10 analysts found an average forecast of a 43 percent
chance of Victoza being approved by the U.S. Food and Drug
Administration as an obesity treatment, with analysts from
international banks more skeptical than Danish peers.
Five analysts from international banks produced a 32 percent average
forecast, compared with a forecast for 55 percent from five analysts
from Danish banks.
United Nations data showed rates of obesity doubled in every region of
the world between 1980 and 2008 with half a billion people - or 12
percent of the world's population - now considered obese.
The highest obesity levels are in the Americas, where 26 percent of
adults are obese, the Geneva-based World Health Organisation's (WHO)
annual report on global health showed, adding that one in 10 adults
worldwide has diabetes.
Diabetes puts sufferers at risk of heart disease, kidney failure and
blindness and can carry obesity as a side effect.
While the FDA has not approved any obesity drugs since 1999, Novo
Nordisk rivals Vivus and Arena Pharmaceuticals have been given
positive recommendations by a panel to the FDA on their obesity
candidates.
The FDA is looking into cardiovascular safety in relation to obesity
drugs which may cause weight loss, but at the cost of rising heart
rate.
(Reporting by Shida Chayesteh; Editing by Dan Lalor)
10:17 a.m. CDT, May 24, 2012
COPENHAGEN (Reuters) - Danish group Novo Nordisk's diabetes drug
Victoza has a 43 percent chance of being approved as an obesity
treatment in the United States, according to a Reuters poll which
found Danish bank analysts had the highest expectations.
Novo Nordisk, the world's biggest insulin producer, is in phase three
of studies to use Victoza to treat obesity and expects the treatment
to be launched in the United States late in of 2014 or early 2015.
Liraglutide, an active ingredient in Victoza, has shown it can be
effective in helping obese people losing weight.
A survey of 10 analysts found an average forecast of a 43 percent
chance of Victoza being approved by the U.S. Food and Drug
Administration as an obesity treatment, with analysts from
international banks more skeptical than Danish peers.
Five analysts from international banks produced a 32 percent average
forecast, compared with a forecast for 55 percent from five analysts
from Danish banks.
United Nations data showed rates of obesity doubled in every region of
the world between 1980 and 2008 with half a billion people - or 12
percent of the world's population - now considered obese.
The highest obesity levels are in the Americas, where 26 percent of
adults are obese, the Geneva-based World Health Organisation's (WHO)
annual report on global health showed, adding that one in 10 adults
worldwide has diabetes.
Diabetes puts sufferers at risk of heart disease, kidney failure and
blindness and can carry obesity as a side effect.
While the FDA has not approved any obesity drugs since 1999, Novo
Nordisk rivals Vivus and Arena Pharmaceuticals have been given
positive recommendations by a panel to the FDA on their obesity
candidates.
The FDA is looking into cardiovascular safety in relation to obesity
drugs which may cause weight loss, but at the cost of rising heart
rate.
(Reporting by Shida Chayesteh; Editing by Dan Lalor)
0 new messages